# A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

> **NCT03567642** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Platinum
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03567642
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-12
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567642, "A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03567642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*